Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes comprehensive molecular simulations of the ion channel in its native membrane environment, depicting its open, closed, and inactivated states, and ensemble virtual screening that accounts for conformational mobility in each state. Tentative binding pockets are investigated inside the pore, at the gating region, and in allosteric sites to cover the full spectrum of possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UK17

UPID:
KCND3_HUMAN

ALTERNATIVE NAMES:
Voltage-gated potassium channel subunit Kv4.3

ALTERNATIVE UPACC:
Q9UK17; O60576; O60577; Q14D71; Q5T0M0; Q9UH85; Q9UH86; Q9UK16

BACKGROUND:
The protein Kv4.3, or Potassium voltage-gated channel subfamily D member 3, is integral to the proper functioning of heart and neuronal electrical activity. It is the alpha subunit of voltage-gated potassium channels, crucial for the I(To) and I(Sa) currents, and its activity is modulated through interactions with other subunits.

THERAPEUTIC SIGNIFICANCE:
Given Kv4.3's critical role in conditions like Spinocerebellar ataxia 19 and Brugada syndrome 9, deciphering its functions and interactions opens the door to novel therapeutic approaches for these neurological and cardiac disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.